]>
IRCT2014042117380N1 IRCT 2014-05-12 Vice-chancellor for research -Shahid Sadoughi University of Medical Science The effect of pentoxifylline on improving of anemia in hemodialysis patients The effect of pentoxifylline on improving of anemia hyporesponsive to recombinant human erythropoietin among patients with ESRD on chronic hemodialysis; a randomized, double blind clinical trial 2013-06-22 anticipated 60 Complete https://irct.ir/trial/15995 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment. 1-2 Anemia in patients with hemodialysis. Intervention 1: case group:400 mg of pentoxifylline daily for 4 months. Intervention 2: control group: 1 placebo tablet daily.
public Dr Mohsen Gholinataj
Shahid Sadoughi Hospital, Yazd
Yazd Iran (Islamic Republic of) +98 35 1822 4000 mghnataj@yahoo.com Shahid Sadoughi University of Medical Sciences scientific Dr Farzane Najafi
Shahid Sadoughi Hospital, Yazd
Yazd Iran (Islamic Republic of) +98 35 1822 4000 drfnajafi@ssu.ac.ir Shahid Sadoughi University of Medical Sciences Iran (Islamic Republic of) Inclusion criteria: all patients with chronic hemodialysis who had hemoglobin level less than 11 gr/dL despite receiving 100-200 IU/Kg/W recombinant erythropoietin at least 3 months before starting the study. Exclusion criteria: age< 18 years old; pregnancy; past history of allergy or intolerance to Pentoxiphyllin; the use of hemodialysis catheter in a recent month; paients with active ulcer disease or dyspepsia; major surgery within 3 months ago; blood transfusion in past month; history of myocardial infarction, stroke and brain hemorrhage in 3 months ago; suboptimal dialysis in recent 2 months ( KT/V < 1.2 ); PTH > 300 pg/mL; Iron deficiency ( ferritin level < 100 µg/L or TIBC < 20% ); any hospitalization in past month ; the previous history of hematological problems such as hemoglobinopathies. 18 years no limit Both N18 Chronic kidney disease Treatment - Drugs Placebo case group:400 mg of pentoxifylline daily for 4 months control group: 1 placebo tablet daily Mean changes in hemoglobin concentrations. Timepoint: 4 times, monthly. Method of measurement: with CBC. Erythrocyte Sedimentation Rate. Timepoint: each 2 months. Method of measurement: with lab tests. C Reactive Protein. Timepoint: each 2 months. Method of measurement: with lab tests. Vice-chancellor for research -Shahid Sadoughi University of Medical Science Approved 2013-07-21 Shahid Sadoughi University of Medical Sciences,Yazd, Iran Shahid Sadoughi University of Medical Sciences,Yazd, Iran Yazd Iran (Islamic Republic of)